Regeneron clears key moving averages, shares trade below consensus targets

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-28, 13:54.

Regeneron Pharmaceuticals (US75886F1075) sits firmly in the NASDAQ biotechnology roster. The shares last closed at 632.90 US dollars on June 26, 2026, with consensus price targets markedly higher according to analyst compilations.

What analyst data shows

MarketBeat reports that Regeneron Pharmaceuticals, listed under the REGN ticker on NASDAQ, carries a consensus rating of "Moderate Buy" from 27 tracked analysts, with two rating the stock Strong Buy, fifteen at Buy and ten at Hold. MarketBeat consensus overview The average price target in that dataset stands at 792.65 US dollars, implying a substantial gap to the latest share price.

Separate data points, such as PandaForecast and Bitget, cite current values of 632.90 US dollars for the latest session and average analyst targets above 830 US dollars, underscoring that multiple sources see upside relative to the prevailing market level. PandaForecast summary for REGN The stock is covered alongside sector heavyweights such as Amgen and Gilead Sciences, providing a clear peer context in large-cap US biotech.

Recent institutional flows and moving averages

On June 28, 2026 MarketBeat highlighted that Pictet Asset Management Holding SA had reduced its position in Regeneron Pharmaceuticals, selling 30,616 shares, a datapoint that illustrates ongoing portfolio activity among large institutions. Pictet Asset Management filing on REGN The filing notes that Regeneron has a 12-month low of 517.39 US dollars and a 12-month high of 821.11 US dollars, framing the recent trading range.

In the same report, the firm's figures show Regeneron shares trading relative to a 50-day moving average of 663.51 US dollars and a 200-day moving average of 728.45 US dollars, both above the latest close, indicating that the stock currently trades below these longer-term trend markers. MarketBeat technical data on REGN This places Regeneron in a somewhat muted technical position compared with certain biotech peers that trade nearer their moving averages.

The business behind Regeneron

Regeneron Pharmaceuticals develops and commercializes biologic medicines, with Eylea (aflibercept) for retinal diseases and Dupixent (dupilumab), co-developed with Sanofi, among its most commercially important products globally. Regeneron product portfolio overview The company uses its proprietary VelociSuite technologies to discover and produce monoclonal antibodies across multiple therapeutic areas, including immunology, oncology, and rare diseases.

Where the stock trades today

Regeneron shares (US75886F1075) trade on NASDAQ under the REGN ticker. As of the close on 2026-06-26 at 16:00 Eastern Time, the shares traded at 632.90 US dollars.

This article is for informational purposes only and does not constitute investment advice, a recommendation or an offer to buy or sell any financial instrument. All data are based on sources deemed reliable but cannot be guaranteed. Investors should conduct their own research or consult a qualified advisor before making investment decisions.